A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo

Jungsoo Lee, Howard Chu, Hemin Lee, Miri Kim, Dae Suk Kim, Sang Ho Oh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Systemic corticosteroids have been used to arrest the progression of vitiligo. However, side effects have been a constant issue. Objective: We evaluated the clinical efficacy and side effect of oral methylprednisolone (MPD) mini-pulse therapy combined with narrow-band UVB (NBUVB) for adults with non-segmental vitiligo retrospectively. Methods: 32 patients with extensive and/or spreading vitiligo received 0.5 mg/kg MPD on 2 consecutive days per week with NBUVB therapy for at least 3 months. Results: All of the 32 patients (100%) showed progression arrest within 12 weeks. Nineteen out of 32 patients (59.4%) presented repigmentation on more than 25% of lesions. Thirteen patients (40.6%) achieved satisfactory repigmentation in more than 50% of lesions. Only 2 patients discontinued the medication due to gastrointestinal trouble. Conclusion: Oral MPD mini-pulse therapy combined with NBUVB appears effective in arresting vitiligo progression and rapidly inducing repigmentation with minimal side effects.

Original languageEnglish
Pages (from-to)224-229
Number of pages6
JournalDermatology
Volume232
Issue number2
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Vitiligo
Methylprednisolone
Retrospective Studies
Therapeutics
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Lee, Jungsoo ; Chu, Howard ; Lee, Hemin ; Kim, Miri ; Kim, Dae Suk ; Oh, Sang Ho. / A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo. In: Dermatology. 2016 ; Vol. 232, No. 2. pp. 224-229.
@article{16042e04b6ca46ffa4b2fb75c5e71934,
title = "A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo",
abstract = "Background: Systemic corticosteroids have been used to arrest the progression of vitiligo. However, side effects have been a constant issue. Objective: We evaluated the clinical efficacy and side effect of oral methylprednisolone (MPD) mini-pulse therapy combined with narrow-band UVB (NBUVB) for adults with non-segmental vitiligo retrospectively. Methods: 32 patients with extensive and/or spreading vitiligo received 0.5 mg/kg MPD on 2 consecutive days per week with NBUVB therapy for at least 3 months. Results: All of the 32 patients (100{\%}) showed progression arrest within 12 weeks. Nineteen out of 32 patients (59.4{\%}) presented repigmentation on more than 25{\%} of lesions. Thirteen patients (40.6{\%}) achieved satisfactory repigmentation in more than 50{\%} of lesions. Only 2 patients discontinued the medication due to gastrointestinal trouble. Conclusion: Oral MPD mini-pulse therapy combined with NBUVB appears effective in arresting vitiligo progression and rapidly inducing repigmentation with minimal side effects.",
author = "Jungsoo Lee and Howard Chu and Hemin Lee and Miri Kim and Kim, {Dae Suk} and Oh, {Sang Ho}",
year = "2016",
month = "4",
day = "1",
doi = "10.1159/000439563",
language = "English",
volume = "232",
pages = "224--229",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "2",

}

A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo. / Lee, Jungsoo; Chu, Howard; Lee, Hemin; Kim, Miri; Kim, Dae Suk; Oh, Sang Ho.

In: Dermatology, Vol. 232, No. 2, 01.04.2016, p. 224-229.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo

AU - Lee, Jungsoo

AU - Chu, Howard

AU - Lee, Hemin

AU - Kim, Miri

AU - Kim, Dae Suk

AU - Oh, Sang Ho

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background: Systemic corticosteroids have been used to arrest the progression of vitiligo. However, side effects have been a constant issue. Objective: We evaluated the clinical efficacy and side effect of oral methylprednisolone (MPD) mini-pulse therapy combined with narrow-band UVB (NBUVB) for adults with non-segmental vitiligo retrospectively. Methods: 32 patients with extensive and/or spreading vitiligo received 0.5 mg/kg MPD on 2 consecutive days per week with NBUVB therapy for at least 3 months. Results: All of the 32 patients (100%) showed progression arrest within 12 weeks. Nineteen out of 32 patients (59.4%) presented repigmentation on more than 25% of lesions. Thirteen patients (40.6%) achieved satisfactory repigmentation in more than 50% of lesions. Only 2 patients discontinued the medication due to gastrointestinal trouble. Conclusion: Oral MPD mini-pulse therapy combined with NBUVB appears effective in arresting vitiligo progression and rapidly inducing repigmentation with minimal side effects.

AB - Background: Systemic corticosteroids have been used to arrest the progression of vitiligo. However, side effects have been a constant issue. Objective: We evaluated the clinical efficacy and side effect of oral methylprednisolone (MPD) mini-pulse therapy combined with narrow-band UVB (NBUVB) for adults with non-segmental vitiligo retrospectively. Methods: 32 patients with extensive and/or spreading vitiligo received 0.5 mg/kg MPD on 2 consecutive days per week with NBUVB therapy for at least 3 months. Results: All of the 32 patients (100%) showed progression arrest within 12 weeks. Nineteen out of 32 patients (59.4%) presented repigmentation on more than 25% of lesions. Thirteen patients (40.6%) achieved satisfactory repigmentation in more than 50% of lesions. Only 2 patients discontinued the medication due to gastrointestinal trouble. Conclusion: Oral MPD mini-pulse therapy combined with NBUVB appears effective in arresting vitiligo progression and rapidly inducing repigmentation with minimal side effects.

UR - http://www.scopus.com/inward/record.url?scp=84943327363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943327363&partnerID=8YFLogxK

U2 - 10.1159/000439563

DO - 10.1159/000439563

M3 - Article

C2 - 26431053

AN - SCOPUS:84943327363

VL - 232

SP - 224

EP - 229

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 2

ER -